Medinotec (MDNC) EBITDA Margin (2022 - 2026)

Medinotec (MDNC) has reported EBITDA Margin for 5 consecutive years, with 6.82% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 618.0% year-over-year to 6.82%; the trailing twelve-month figure through May 2026 stood at 9.74% (down 2217.0% YoY), and the FY2026 full-year result was 11.25%, down 2377.0% from the prior year.
• EBITDA Margin climbed to 6.82% in Q2 2026 per MDNC's latest filing, from 14.5% in the prior quarter.
• Across five years, EBITDA Margin topped out at 55.58% in Q1 2025 and bottomed at 127.02% in Q3 2022.
• Historically, EBITDA Margin has averaged 1.22% across 5 years, with a median of 11.91% in 2023.
• The sharpest annual moves came in 2023 and 2026: EBITDA Margin soared 14290 bps in 2023, then sank 7008 bps in 2026.
• Over 5 years, EBITDA Margin stood at 6.57% in 2022, then jumped by 96 bps to 12.88% in 2023, then soared by 60 bps to 20.56% in 2024, then advanced by 6 bps to 21.79% in 2025, then plunged by 69 bps to 6.82% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 6.82%, 14.5%, and 21.79% for Q2 2026, Q1 2026, and Q4 2025 respectively.